This is a contrast between DBV Technologies S.A. (NASDAQ:DBVT) and Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) based on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DBV Technologies S.A.||N/A||0.00||N/A||-3.27||0.00|
|Imprimis Pharmaceuticals Inc.||N/A||0.00||N/A||-0.31||0.00|
Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for DBV Technologies S.A. and Imprimis Pharmaceuticals Inc.
Table 2 shows the return on assets, return on equity and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|DBV Technologies S.A.||0.00%||0%||0%|
|Imprimis Pharmaceuticals Inc.||0.00%||-230.7%||-25.2%|
The table given features the ratings and recommendations for DBV Technologies S.A. and Imprimis Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|DBV Technologies S.A.||0||3||3||2.50|
|Imprimis Pharmaceuticals Inc.||0||0||1||3.00|
DBV Technologies S.A.’s average target price is $20.6, while its potential upside is 172.13%. Competitively the average target price of Imprimis Pharmaceuticals Inc. is $10, which is potential 75.75% upside. The data from earlier shows that analysts view suggest that DBV Technologies S.A. seems more appealing than Imprimis Pharmaceuticals Inc.
Institutional and Insider Ownership
The shares of both DBV Technologies S.A. and Imprimis Pharmaceuticals Inc. are owned by institutional investors at 45.03% and 23.3% respectively. Comparatively, insiders own roughly 3.9% of Imprimis Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|DBV Technologies S.A.||-7.55%||-30.3%||-37.31%||-34.86%||-34.24%||-43.25%|
|Imprimis Pharmaceuticals Inc.||14.8%||23.69%||79.8%||118.95%||213.87%||219.41%|
For the past year DBV Technologies S.A. had bearish trend while Imprimis Pharmaceuticals Inc. had bullish trend.
On 4 of the 7 factors Imprimis Pharmaceuticals Inc. beats DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for CrohnÂ’s disease and respiratory syncytial virus. The company has collaboration with NestlÃ© Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The companyÂ’s medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.